Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

PR Newswire April 2, 2024

Cancer and the Combination Approach

Accesswire March 28, 2024

Jazz Pharmaceuticals Celebrates International Women's Day

Accesswire March 20, 2024

Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month

Accesswire March 14, 2024

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

PR Newswire March 12, 2024

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

PR Newswire February 28, 2024

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

PR Newswire February 27, 2024

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

PR Newswire February 21, 2024

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

PR Newswire February 20, 2024

Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024

PR Newswire February 14, 2024

Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals

Accesswire February 13, 2024

How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1

Accesswire February 9, 2024

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

PR Newswire February 7, 2024

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder

PR Newswire December 21, 2023

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire December 20, 2023

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

PR Newswire December 8, 2023

Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global Communities

Accesswire December 8, 2023

Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting

PR Newswire December 1, 2023

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings

PR Newswire November 30, 2023

Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Using Natural Resources Responsibly

Accesswire November 29, 2023